BioSpace News Archive

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/PME eligible), Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced positive results (topline data) for the Phase IIA study1 of VALEDIA® (active substance: TOTUM-63), which evaluated this product’s efficacy in a prediabetic population, compared to placebo.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has approved ULTOMIRIS® (ravulizumab)

Endeavors is pleased to announce the appointment of Adriana Wilson as Deputy Development Officer.

In a study published online in Nature, researchers at Albert Einstein College of Medicine describe the first complete wiring diagram of the nervous system of an animal, the roundworm Caenorhabditis elegans, used by scientists worldwide as a model organism.

Hesperos Inc., pioneers of the “human-on-a-chip” in vitro system has announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known cardiotoxic small molecules over time, to accurately describe the drug behavior and toxic effects in vivo

The world’s middle class is booming, and Asia is at the crux of it. The World Economic Forum estimates the middle class will expand to 5.3 billion people by 2030, up from 3.6 billion today.

ResMed (NYSE: RMD) (ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2019 on Thursday, July 25, 2019, after the New York Stock Exchange closes.

Onco360®, the nation’s largest independent Oncology Pharmacy, announced today that it was selected to be a specialty pharmacy network partner for Karyopharm’s new product XPOVIO™ (selinexor

Responsible Telemedicine, an organization devoted to promoting accessible and proper healthcare, has generously donated $4,100 to further the efforts of World Telehealth Initiative.

Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced its financial and operational results for the year ended March 31, 2019.